嘉应制药
(002198)
| 流通市值：30.91亿 | | | 总市值：30.91亿 |
| 流通股本：5.08亿 | | | 总股本：5.08亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 264,960,176.44 | 336,141,154.38 | 216,891,217.73 | 171,519,328.83 |
| 应收票据及应收账款 | 159,322,251.66 | 106,449,472.04 | 102,500,776.24 | 111,021,909.42 |
| 其中：应收票据 | 27,751,144.43 | 29,457,997.77 | 9,023,906.58 | 11,997,001.69 |
| 应收账款 | 131,571,107.23 | 76,991,474.27 | 93,476,869.66 | 99,024,907.73 |
| 应收款项融资 | 24,274,557.59 | 22,477,878.29 | 4,106,604 | 8,561,645.71 |
| 预付款项 | 1,011,340.51 | 1,634,160.12 | 24,961,016.51 | 2,296,508.27 |
| 其他应收款合计 | 1,083,268.07 | 1,161,007.24 | 2,518,475.51 | 6,647,481.72 |
| 存货 | 74,294,875.18 | 85,061,270.13 | 87,158,970.46 | 97,431,990 |
| 其他流动资产 | 908,765.57 | 833,422.06 | 340,934.54 | 1,611,828.51 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 529,345,611.02 | 553,758,364.26 | 518,605,435.65 | 539,253,639.97 |
| 非流动资产: | | | | |
| 长期股权投资 | 22,897,065.05 | 23,303,717.52 | 24,295,644.89 | 25,313,532.43 |
| 固定资产 | 176,450,771.13 | 180,951,372.14 | 179,475,578.29 | 181,059,003.69 |
| 在建工程 | 31,340,384.36 | 29,056,017.97 | 16,984,641.27 | 6,705,524.12 |
| 无形资产 | 45,587,895.55 | 45,891,040.66 | 46,298,734.32 | 46,549,605.15 |
| 长期待摊费用 | 1,697,496.71 | 1,401,315.26 | 469,402.7 | 190,773.8 |
| 递延所得税资产 | 3,027,430.27 | 3,029,863.9 | 2,443,200.68 | 2,553,332.41 |
| 其他非流动资产 | 2,289,264 | 1,428,760 | 7,440,371.5 | 14,419,832 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 283,290,307.07 | 285,062,087.45 | 277,407,573.65 | 276,791,603.6 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 812,635,918.09 | 838,820,451.71 | 796,013,009.3 | 816,045,243.57 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 11,606,617.68 | 12,607,576.55 | 2,327,087.37 | 13,906,939.33 |
| 应付账款 | 11,606,617.68 | 12,607,576.55 | 2,327,087.37 | 13,906,939.33 |
| 合同负债 | 1,926,390.4 | 2,879,914.51 | 646,107.03 | 2,477,184.87 |
| 应付职工薪酬 | 3,216,546.7 | 4,771,083.19 | 3,547,493.07 | 3,216,146.3 |
| 应交税费 | 13,395,298.92 | 6,889,321.14 | 4,968,593.88 | 3,412,524.71 |
| 其他应付款合计 | 23,089,725.27 | 14,868,696.72 | 8,838,319.37 | 12,268,383.25 |
| 其他流动负债 | 250,430.76 | 3,548,773.85 | 79,382.23 | 2,365,520.52 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 53,485,009.73 | 45,565,365.96 | 20,406,982.95 | 37,646,698.98 |
| 非流动负债: | | | | |
| 递延收益 | 256,156.72 | 287,594.89 | 319,033.06 | 350,471.23 |
| 递延所得税负债 | 34,746,735.76 | 34,746,735.76 | 34,804,491.79 | 34,771,177.89 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 35,002,892.48 | 35,034,330.65 | 35,123,524.85 | 35,121,649.12 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 88,487,902.21 | 80,599,696.61 | 55,530,507.8 | 72,768,348.1 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 507,509,848 | 507,509,848 | 507,509,848 | 507,509,848 |
| 资本公积 | 123,652,931.39 | 123,652,931.39 | 123,652,931.39 | 123,652,931.39 |
| 减:库存股 | 49,475,996.4 | 0 | - | - |
| 盈余公积 | 27,767,450.89 | 27,767,450.89 | 27,223,004.6 | 27,223,004.6 |
| 未分配利润 | 114,693,782 | 99,290,524.82 | 82,096,717.51 | 84,891,111.48 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 724,148,015.88 | 758,220,755.1 | 740,482,501.5 | 743,276,895.47 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 724,148,015.88 | 758,220,755.1 | 740,482,501.5 | 743,276,895.47 |
| 负债和股东权益合计 | 812,635,918.09 | 838,820,451.71 | 796,013,009.3 | 816,045,243.57 |
| 公告日期 | 2025-04-26 | 2025-04-26 | 2024-10-31 | 2024-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |